Chitosan Dressing for Bleeding Control in Transurethral Prostatectomy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for controlling bleeding during and after transurethral resection of the prostate (TURP) are inadequate, particularly in managing venous bleeding, which is difficult to control and often leads to prolonged hospital stays, increased costs, and complications such as urinary tract infections and clot retention.

Innovation Solution

A chitosan endoluminal hemostatic dressing (CEHD) that is specifically designed for rapid bleeding control, capable of adhering to tissue in the presence of anticoagulants, promoting healing, and allowing for non-surgical removal within 7 days, reducing the need for prolonged catheterization and hospital stays.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If electrocautery is used to control arterial bleeding, then arterial bleeding is easily controlled, but intraoperative bleeding increases due to tissue necrosis

Engineering Contradiction:

Improvearterial bleeding controlVSAvoidtissue necrosis

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The chitosan dressing acts as an intermediary hemostatic agent between the injury site and the patient's coagulation system. It provides a physical matrix that promotes clot formation and stabilizes the clot at the injury site, effectively controlling arterial bleeding without the thermal damage caused by electrocautery.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention replaces the thermal/mechanical system of electrocautery with a chemical/biological system based on chitosan's hemostatic properties. The dressing utilizes chitosan's ability to interact with blood components to form clots, substituting the harmful thermal necrosis with a gentler chemical hemostatic mechanism.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If balloon pressure is applied to control venous bleeding, then venous oozing is addressed, but bleeding control is inadequate and hospital stay is prolonged

Engineering Contradiction:

Improvevenous bleeding controlVSAvoidhospital stay duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The chitosan dressing changes the hemostatic parameters by providing a scaffold that enhances platelet activation and clot stability. This allows effective venous bleeding control at lower pressures and for shorter durations compared to traditional balloon catheter application, thereby reducing hospital stay.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The dressing utilizes composite material properties of chitosan, which combines adsorption capabilities, biocompatibility, and hemostatic promotion. This composite approach provides superior venous bleeding control compared to simple mechanical compression alone.

Inventive Principle:

Principle #40Composite materials

3Reliability

If prolonged balloon catheter application is used for hemostasis, then bleeding control is maintained, but urinary tract infections and clot retention complications increase

Engineering Contradiction:

Improvehemostasis maintenanceVSAvoidurinary tract infections

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The chitosan dressing provides sufficient hemostatic action through its chemical and physical properties, requiring only partial application time compared to prolonged balloon catheter use. This partial action approach achieves effective hemostasis while minimizing the duration of catheterization and associated infection risks.

Inventive Principle:

Principle #16Partial or excessive action

4Reliability

If standard conservative management is applied for bleeding control, then initial hemostasis is achieved, but bleeding recurs when scab sheds off

Engineering Contradiction:

Improveinitial hemostasisVSAvoidhemostasis duration

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The chitosan dressing performs preliminary action by establishing a stable clot and promoting wound healing from the outset. It creates a protective matrix that maintains hemostasis throughout the healing process, preventing recurrent bleeding when the scab sheds, unlike standard conservative management that only provides temporary initial hemostasis.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CEHD effectively reduces the incidence of uncontrolled hemorrhage, shortens catheterization time, decreases hospital stay duration, and lowers healthcare costs by providing a reliable and sustainable hemostatic solution for TURP procedures.

Implementation Method 1

capable of adhering to tissue in the presence of anticoagulants

Methodology Applied

Scientific EffectAdhesion: Adhesive

Implementation Method 2

Chitosan endoluminal hemostatic dressing (CEHD) that is specifically designed for rapid bleeding control

Methodology Applied

Scientific EffectCoagulation: Coagulation

Data Source

PatentUS12156791B2Chitosan dressing for control of bleeding in transurethral prostatectomy

Publication Date: 2024.12.03 TRICOL BIOMEDICAL INC

AI summary

The present invention relates to a biocompatible, foldable, thin profile, low mass and high surface area, chitosan dressing, optionally modified with catechol, and suitable for treating bleeding in a physiological environment, e.g. bladder, and in particular in connection with the TURP procedure. The characteristics and structures of the chitosan dressing are provided. Methods of making and using the chitosan dressing are also provided.